Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years
• Ability to understand and willingness to sign a written informed consent document
• Diagnosed with soft tissue sarcoma
• Undergoing resection of lung lesion as part of standard care
Locations
Other Locations
Canada
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
RECRUITING
Toronto
Contact Information
Primary
David Shultz
david.shultz@uhn.ca
416-946-4501
Time Frame
Start Date: 2025-01-29
Estimated Completion Date: 2032-04-01
Participants
Target number of participants: 70
Treatments
Experimental: Routine Bronchoscopy & SOC Metastasectomy
BALF and TA will be collected during routine bronchoscopy, and resected lung metastases and adjacent normal tissue will be collected during standard of care metastasectomy
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto